Tags

Type your tag names separated by a space and hit enter

Efficacy of narrowband UVB vs. PUVA in patients with early-stage mycosis fungoides.
J Eur Acad Dermatol Venereol. 2010 Jun; 24(6):716-21.JE

Abstract

INTRODUCTION

Mycosis fungoides (MF) is a non-Hodgkin's T-cell lymphoma of the skin that often begins as limited patches and plaques with slow progression to systemic involvement. Narrowband ultraviolet (UV) B therapy has been proven to be an effective short-term treatment modality for clearing patch-stage MF. The effect of psoralen plus long-wave ultraviolet A (PUVA) in the treatment of patch- and plaque-type MF has also been thoroughly documented.

OBJECTIVES

The purpose of this study was to compare the efficacy and safety of narrowband UVB and PUVA in patients with early-stage MF.

METHODS

We analysed the response to treatment, relapse-free survival and irradiation dose in 114 patients with histologically confirmed early-stage MF (stage IA, IB and IIA).

RESULTS

A total of 95 patients were treated with PUVA (83.3%) and 19 with narrowband UVB (16.7%). With PUVA, 59 patients (62.1%) had a complete response (CR), 24 (25.3%) had a partial response (PR) and 12 (12.6%) had a failed response. Narrowband UVB led to CR in 12 (68.4%) patients, PR in 5 (26.3%) patients and a failed response in 1 (5.3%) patient. There were no differences in terms of time to relapse between patients treated with PUVA and those treated with narrowband UVB (11.5 vs. 14.0 months respectively; P = 0.816). No major adverse reactions were attributed to the treatment.

CONCLUSIONS

Our results confirm that phototherapy is a safe, effective and well-tolerated, first-line therapy in patients with early-stage cutaneous T-cell lymphoma, with prolonged disease-free remissions being achieved. It suggests that narrowband UVB is at least as effective as PUVA for treatment of early-stage MF.

Authors+Show Affiliations

Department of Dermatology, Hospital dos Capuchos, Centro Hospitalar de Lisboa Central, Lisbon, Portugal. pedrofponte@gmail.comNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

19929938

Citation

Ponte, P, et al. "Efficacy of Narrowband UVB Vs. PUVA in Patients With Early-stage Mycosis Fungoides." Journal of the European Academy of Dermatology and Venereology : JEADV, vol. 24, no. 6, 2010, pp. 716-21.
Ponte P, Serrão V, Apetato M. Efficacy of narrowband UVB vs. PUVA in patients with early-stage mycosis fungoides. J Eur Acad Dermatol Venereol. 2010;24(6):716-21.
Ponte, P., Serrão, V., & Apetato, M. (2010). Efficacy of narrowband UVB vs. PUVA in patients with early-stage mycosis fungoides. Journal of the European Academy of Dermatology and Venereology : JEADV, 24(6), 716-21. https://doi.org/10.1111/j.1468-3083.2009.03500.x
Ponte P, Serrão V, Apetato M. Efficacy of Narrowband UVB Vs. PUVA in Patients With Early-stage Mycosis Fungoides. J Eur Acad Dermatol Venereol. 2010;24(6):716-21. PubMed PMID: 19929938.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy of narrowband UVB vs. PUVA in patients with early-stage mycosis fungoides. AU - Ponte,P, AU - Serrão,V, AU - Apetato,M, Y1 - 2009/11/19/ PY - 2009/11/26/entrez PY - 2009/11/26/pubmed PY - 2010/10/12/medline SP - 716 EP - 21 JF - Journal of the European Academy of Dermatology and Venereology : JEADV JO - J Eur Acad Dermatol Venereol VL - 24 IS - 6 N2 - INTRODUCTION: Mycosis fungoides (MF) is a non-Hodgkin's T-cell lymphoma of the skin that often begins as limited patches and plaques with slow progression to systemic involvement. Narrowband ultraviolet (UV) B therapy has been proven to be an effective short-term treatment modality for clearing patch-stage MF. The effect of psoralen plus long-wave ultraviolet A (PUVA) in the treatment of patch- and plaque-type MF has also been thoroughly documented. OBJECTIVES: The purpose of this study was to compare the efficacy and safety of narrowband UVB and PUVA in patients with early-stage MF. METHODS: We analysed the response to treatment, relapse-free survival and irradiation dose in 114 patients with histologically confirmed early-stage MF (stage IA, IB and IIA). RESULTS: A total of 95 patients were treated with PUVA (83.3%) and 19 with narrowband UVB (16.7%). With PUVA, 59 patients (62.1%) had a complete response (CR), 24 (25.3%) had a partial response (PR) and 12 (12.6%) had a failed response. Narrowband UVB led to CR in 12 (68.4%) patients, PR in 5 (26.3%) patients and a failed response in 1 (5.3%) patient. There were no differences in terms of time to relapse between patients treated with PUVA and those treated with narrowband UVB (11.5 vs. 14.0 months respectively; P = 0.816). No major adverse reactions were attributed to the treatment. CONCLUSIONS: Our results confirm that phototherapy is a safe, effective and well-tolerated, first-line therapy in patients with early-stage cutaneous T-cell lymphoma, with prolonged disease-free remissions being achieved. It suggests that narrowband UVB is at least as effective as PUVA for treatment of early-stage MF. SN - 1468-3083 UR - https://www.unboundmedicine.com/medline/citation/19929938/Efficacy_of_narrowband_UVB_vs__PUVA_in_patients_with_early_stage_mycosis_fungoides_ L2 - https://doi.org/10.1111/j.1468-3083.2009.03500.x DB - PRIME DP - Unbound Medicine ER -